GPC1 Knockout cell line (BxPC-3)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

GPC1 (glypican 1) encodes a glycosylphosphatidylinositol-anchored cell-surface heparan sulfate proteoglycan. Its extracellular heparan sulfate chains can participate in interactions with signaling molecules and cell-surface components. GPC1 is involved in regulation of cell division and growth and contributes to cell-surface organization and signaling processes mediated by membrane-associated proteoglycans.

BxPC-3 is a human pancreatic adenocarcinoma cell line established from a primary tumor of the pancreatic body of a 61-year-old female patient. The cells produce mucin and form xenograft tumors in nude mice that exhibit moderately well to poorly differentiated characteristics similar to the original tumor. BxPC-3 cells are described as lacking cystic fibrosis transmembrane conductance regulator (CFTR) expression. The cell line is widely used as a model for studying pancreatic cancer biology, tumor progression, mucin production, and therapeutic responses.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.